Prostate News and Research

RSS

Cryotherapy offers potential treatment options for breast cancer patients

Interventional radiologists have opened the door to an encouraging potential future treatment for the nearly 200,000 women who are diagnosed with breast cancer in the United States each year: image-guided, multiprobe cryotherapy.

17 Mar 2010

Key cellular defect in protein synthesis can lead to cancer susceptibility

UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.

17 Mar 2010

Levels of perceived cancer risk can affect health and longevity

Mammograms, pap smears and early detection tests for prostate cancer, colorectal cancer and other malignancies are critical for catching cancer before it becomes deadly.

16 Mar 2010

Study offers new possibilities for breast and other cancer therapies

Conventional biological wisdom holds that living cells interact with their environment through an elaborate network of chemical signals. As a result many therapies for the treatment of cancer and other diseases in which cell behavior goes awry focus on drugs that block or disrupt harmful chemical signals.

16 Mar 2010

GTx reacquires full rights to Ostarine

GTx, Inc. today provided a company update and reported financial results for the fourth quarter and full year 2009.

15 Mar 2010

Multimedia software program developed to help prostate cancer patients make treatment decisions

Mount Sinai School of Medicine is leading a study of patients newly-diagnosed with prostate cancer to determine if providing them with multimedia materials can help them make more informed treatment decisions. Michael Diefenbach, Ph.D., Associate Professor of Urology at Mount Sinai School of Medicine developed a multimedia software program designed to help prostate cancer patients and their families make treatment decisions.

15 Mar 2010

New method to better study prostate cancer

Van Andel Research Institute researchers have developed a new method to better study the cells that line and protect the prostate in relation to the development of cancer. Using the model, they found that normal cells and cancer cells depend on different factors to survive, which could aid in discovering how to target cancer cells without affecting normal cells when developing treatments.

12 Mar 2010

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.

12 Mar 2010

Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC

Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).

12 Mar 2010

Genentech announces topline results from Phase III trial of Avastin

Genentech, Inc., a wholly owned member of the Roche Group, announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC).

12 Mar 2010

PSA test is still the best option for diagnosing prostate cancer

When it comes to the documented 40 percent effectiveness of PSA testing in preventing death from prostate cancer, neither the American Cancer Society nor the discoverer of the PSA protein, Richard Ablin, are telling the public the complete story.

12 Mar 2010

Abbott's sNDA for new six-month 45-mg formulation of Lupron Depot: FDA accepts for review

The U.S. Food and Drug Administration has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron® Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer. Palliative treatment helps to relieve symptoms associated with advanced prostate cancer.

12 Mar 2010

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.

11 Mar 2010

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company’s 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.

11 Mar 2010

Extreme or moderate heat may help cure malignant and benign tumors

Aided by ultrasound guidance, treating tumors with extreme heat or moderate heat may provide a possible therapeutic option, according to early research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held March 7-10, 2010.

11 Mar 2010

Study supports Myriad Genetics' PROLARIS molecular diagnostic test for predicting prostate cancer recurrence

Myriad Genetics, Inc. today said data that provides further clinical validation supporting its newest molecular diagnostic product, PROLARIS™, was recently presented at the 2010 Genitourinary Cancers Symposium in San Francisco. The abstract of the presentation entitled: "Cell Cycle Genes Predict Recurrence After Radical Prostatectomy" by Gregory P. Swanson, M.D., University of Texas Health Science Center San Antonio, and colleagues is now available on the American Society of Clinical Oncology's website, www.asco.org.

11 Mar 2010

Genetic mutation in African-American men with family history of prostate cancer discovered

Shahriar Koochekpour, MD, PhD, Assistant Professor of Microbiology and Immunology, Biochemistry and Molecular Biology, and Genetics at LSU Health Sciences Center New Orleans, led research that has discovered, for the first time, a genetic mutation in African-American men with a family history of prostate cancer who are at increased risk for the disease.

11 Mar 2010

Bavarian Nordic' Annual Report 2009

Today Bavarian Nordic published the company's Annual Report 2009. The report is available on the company's website: www.bavarian-nordic.com

10 Mar 2010

African-Americans and Hispanics are at higher risk for developing Alzheimer's and dementias

According to the Alzheimer's Association's® 2010 Alzheimer's Disease Facts and Figures, African-Americans are about two times more likely and Hispanics are about one and one-half times more likely than their white counterparts to have Alzheimer's and other dementias.

10 Mar 2010

Two core premises underlie MSI's mission to broaden access to surgical choice and quality

Two core premises underlie Mobile Surgery International's mission to broaden access to surgical choice and quality. The first is that patients (and payers) should be able to make decisions about surgical options based upon access to complete information up front about all of the necessary services associated with their surgical procedure, the skill and expertise of the surgeon carrying out the procedure, and the total costs involved.

10 Mar 2010

Prostate News and Research

Cryotherapy offers potential treatment options for breast cancer patients

Key cellular defect in protein synthesis can lead to cancer susceptibility

Levels of perceived cancer risk can affect health and longevity

Study offers new possibilities for breast and other cancer therapies

GTx reacquires full rights to Ostarine

Multimedia software program developed to help prostate cancer patients make treatment decisions

New method to better study prostate cancer

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC

Genentech announces topline results from Phase III trial of Avastin

PSA test is still the best option for diagnosing prostate cancer

Abbott's sNDA for new six-month 45-mg formulation of Lupron Depot: FDA accepts for review

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Extreme or moderate heat may help cure malignant and benign tumors

Study supports Myriad Genetics' PROLARIS molecular diagnostic test for predicting prostate cancer recurrence

Genetic mutation in African-American men with family history of prostate cancer discovered

Bavarian Nordic' Annual Report 2009

African-Americans and Hispanics are at higher risk for developing Alzheimer's and dementias

Two core premises underlie MSI's mission to broaden access to surgical choice and quality

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News